博瑞医药
(688166)
| 流通市值：219.51亿 | | | 总市值：219.51亿 |
| 流通股本：4.23亿 | | | 总股本：4.23亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 874,249,705.24 | 537,438,662.14 | 248,959,843.43 | 1,282,551,614.5 |
| 营业收入 | 874,249,705.24 | 537,438,662.14 | 248,959,843.43 | 1,282,551,614.5 |
| 二、营业总成本 | 859,671,361.36 | 549,542,369.7 | 266,560,026.02 | 1,102,598,723.72 |
| 营业成本 | 424,926,677.5 | 275,665,557.36 | 139,552,951.79 | 544,950,815.79 |
| 税金及附加 | 8,904,941.78 | 5,473,900.07 | 2,686,271.42 | 8,419,669.89 |
| 销售费用 | 61,771,544.27 | 39,649,202.67 | 17,425,476.55 | 71,743,054.11 |
| 管理费用 | 113,542,725.05 | 70,728,331.17 | 34,507,017.62 | 139,123,381.53 |
| 研发费用 | 216,428,186.84 | 138,287,639.33 | 61,638,706.67 | 297,452,702.27 |
| 财务费用 | 34,097,285.92 | 19,737,739.1 | 10,749,601.97 | 40,909,100.13 |
| 其中:利息费用 | 48,369,730.43 | 29,026,886.6 | 14,972,467.48 | 52,435,026.77 |
| 其中:利息收入 | 7,958,528.43 | 2,966,294.54 | 1,141,673.27 | 10,963,526.58 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,513,855.64 | 1,585,851.81 | 1,722,160.93 | -5,699,782.83 |
| 加:投资收益 | -11,753,984.38 | -5,427,848.31 | -1,112,645.51 | -11,633,803.45 |
| 资产减值损失(新) | -2,756,862.56 | -2,766,161.91 | 708,012.2 | -19,942,512.38 |
| 信用减值损失(新) | 3,127,119.97 | 3,496,034.52 | -3,203,261.81 | -12,353,172.29 |
| 其他收益 | 18,064,813.94 | 10,393,707.71 | 7,589,558.61 | 29,965,430.1 |
| 四、营业利润 | 22,773,286.49 | -4,822,123.74 | -11,896,358.17 | 160,289,049.93 |
| 加:营业外收入 | 178,434.88 | 135,150.78 | 99,446.12 | 48,309.78 |
| 减:营业外支出 | 536,922.71 | 334,252.39 | 66,966.84 | 3,136,751.31 |
| 五、利润总额 | 22,414,798.66 | -5,021,225.35 | -11,863,878.89 | 157,200,608.4 |
| 减:所得税费用 | -8,971,726.09 | -6,678,301.82 | -7,207,107.71 | 15,937,323.86 |
| 六、净利润 | 31,386,524.75 | 1,657,076.47 | -4,656,771.18 | 141,263,284.54 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 31,386,524.75 | 1,657,076.47 | -4,656,771.18 | 141,263,284.54 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 50,320,017.34 | 17,173,195.68 | 12,959,776.09 | 189,166,937.36 |
| 少数股东损益 | -18,933,492.59 | -15,516,119.21 | -17,616,547.27 | -47,903,652.82 |
| 扣除非经常损益后的净利润 | 46,172,260.19 | 14,368,619.87 | 8,033,775.13 | 180,507,497.62 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.04 | 0.03 | 0.45 |
| (二)稀释每股收益 | 0.12 | 0.04 | 0.03 | 0.45 |
| 八、其他综合收益 | -2,579,713.14 | -2,579,713.14 | -70,221.14 | -37,833,359.39 |
| 归属于母公司股东的其他综合收益 | -2,579,713.14 | -2,579,713.14 | -70,221.14 | -37,833,359.39 |
| 九、综合收益总额 | 28,806,811.61 | -922,636.67 | -4,726,992.32 | 103,429,925.15 |
| 归属于母公司股东的综合收益总额 | 47,740,304.2 | 14,593,482.54 | 12,889,554.95 | 151,333,577.97 |
| 归属于少数股东的综合收益总额 | -18,933,492.59 | -15,516,119.21 | -17,616,547.27 | -47,903,652.82 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-18 | 2025-04-03 |
| 审计意见(境内) | | | | 标准无保留意见 |